Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Rheumatol ; 39(2): 232-241, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38933720

ABSTRACT

Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software. Results: The mean age of the elderly patients was 67±5.8 years, while the mean age of the younger patients was 49.2±10.9 years. Male predominance was lower in the older AS group compared to the younger AS group (p=0.002). During follow-up period, 397 patients (comprising 318 young and 79 elderly individuals) had a history of using at least one biological disease-modifying agent (bDMARD). There was no significant difference between the groups in terms of DMARD and bDMARD-use distributions. First tumor necrosis factor inhibitor (TNFi) retention rates were found to be similar in both groups over 10 years of follow-up. Adverse events were found to be similar in young (19.9%) and elderly (26.8%) AS patients. Conclusion: Research in the TURKBIO cohort reveals that both older and younger patients with AS exhibited similar disease activity levels with comparable treatment approaches. Moreover, the results of TNFi treatments in elderly patients were the same as those observed in younger patients, with no notable increase in safety concerns.

2.
Sci Rep ; 14(1): 14194, 2024 06 20.
Article in English | MEDLINE | ID: mdl-38902436

ABSTRACT

Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01-1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.


Subject(s)
Registries , Spondylitis, Ankylosing , Humans , Spondylitis, Ankylosing/drug therapy , Male , Female , Middle Aged , Adult , Treatment Outcome , Tumor Necrosis Factor Inhibitors/therapeutic use , Tumor Necrosis Factor Inhibitors/adverse effects , Age of Onset , Antirheumatic Agents/therapeutic use , Antirheumatic Agents/adverse effects , Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.
Medicine (Baltimore) ; 91(3): 131-136, 2012 May.
Article in English | MEDLINE | ID: mdl-22543627

ABSTRACT

We assessed the risk factors and causes of death in patients with familial Mediterranean fever (FMF) in an era when colchicine is the standard therapy for all patients.This study included all FMF patients who had presented to any of the internal medicine, rheumatology, or nephrology clinics at Dokuz Eylul University Hospital between 1992 and 2009. Of the 650 patients with FMF identified, 587 (90.3%) had either a face-to-face (n = 380) or telephone (n = 193) interview, or were confirmed as deceased. A structured questionnaire was used to obtain socioeconomic and demographic data, presenting and cumulative clinical features, and disease severity scores.During the follow-up period mortality was analyzed by calculating age- and sex-standardized mortality ratio (SMR) according to the mortality statistics of the Turkish population. Factors predictive of mortality were evaluated using Kaplan-Meier and Cox proportional hazard models. Sixty-three (9.7%) patients whose initial demographic and major clinical characteristics were similar to the rest of the group could not be contacted during the study period.Most (94.2%) patients were on colchicine at the time of the study. Thirty-seven (6.3%) patients had biopsy-verified amyloidosis, and 44 (7.5%) had renal disease. During a median follow-up of 6 years, 14 patients (9 women) died, and amyloidosis and its related complications were the leading causes of death in 7 patients. Univariate analysis revealed that increasing age, coronary heart disease, hypertension, renal disease, and amyloidosis were associated with mortality. However, Cox regression analysis showed amyloidosis as the only significant predictor of mortality (p < 0.001). The overall patient survival rate was not significantly different from the age- and sex-matched Turkish general population (SMR, 1.48; 95% confidence interval, 0.817-2.49).Our findings suggest that although the survival of FMF patients in the colchicine era is comparable to that of the general population, renal involvement still predicts mortality.


Subject(s)
Amyloidosis/epidemiology , Colchicine/therapeutic use , Familial Mediterranean Fever/mortality , Amyloidosis/complications , Cause of Death , Familial Mediterranean Fever/complications , Familial Mediterranean Fever/drug therapy , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Prognosis , Proportional Hazards Models , Risk Factors , Surveys and Questionnaires , Survival Analysis , Turkey
5.
Rheumatol Int ; 29(3): 343-5, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18704427

ABSTRACT

Involvement of the axial skeleton in sarcoidosis is a rare condition. Herein we report a case with an extensive axial sarcoidosis whose plain radiographs were non-informative. The present case suggested that osseous lesions on sacrum and iliac bones might cause misdiagnosis of sacroiliitis in plain radiographs and advanced imaging may be necessary to make an accurate diagnosis. Our case also underscores the importance of magnetic resonance imaging in selection of a suitable biopsy site to establish diagnosis.


Subject(s)
Sarcoidosis , Female , Humans , Ilium/pathology , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging , Middle Aged , Radiography , Sarcoidosis/complications , Sarcoidosis/diagnosis , Sarcoidosis/diagnostic imaging , Sarcoidosis, Pulmonary/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...